Hikal Quarterly Results for Trading Insights
In Sept 2025, Hikal (HIKAL) reported revenue ₹318 Cr and net profit ₹-35 Cr — revenue -29.5% YoY. Also explore Hikal share price performance to track price trends across different timeframes.
HIKAL Quarterly Results — Revenue, Profit & EPS Highlights
Hikal latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Hikal share price screener.
- Revenue of ₹318 Cr in Sept 2025 (-42.3% vs Mar 2025, -29.5% vs Sept 2024)
- Net Profit of ₹-35 Cr in Sept 2025 (-170.0% vs Mar 2025, -294.4% vs Sept 2024)
- EBITDA of ₹7 Cr in Sept 2025 (-94.3% vs Mar 2025)
- Operating Margin of 2.0% in Sept 2025 (-20.0pp vs Mar 2025)
- Earnings Per Share of ₹-2.83 in Sept 2025 (-169.5% vs Mar 2025)
Hikal Quarterly Results — Revenue, EBITDA, Net Profit & EPS
HIKAL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 318 | 551 | 372 | 494 | 451 | -42.3% | -29.5% |
| Net Profit (₹ Cr) | -35 | 50 | -22 | -6 | 18 | - | - |
| EBITDA (₹ Cr) | 7 | 122 | 17 | 44 | 73 | - | - |
| EPS (₹) | -2.83 | 4.07 | -1.82 | -0.48 | 1.48 | - | - |
| Operating Margin (%) | 2.0% | 22.0% | 4.0% | 8.0% | 16.0% | - | - |
HIKAL Share Price Trend — 1-Year Movement Across Quarterly Results
Hikal 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with Hikal valuation methods to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
HIKAL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Hikal latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores